Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14764)	9/19/2000 11:18:48 PM
From: Robert K.	Respond to of 17367

Cacaito, your comments >"The meningo rbpi21 trial was a very good effort, it was scientifically successful, it showed big promise, baxter chose a good but uncertain candidate, FDA did its job. xoma is in good shape with two drug platform in development (anticd11a, and yes rbpi21), they have many good partners, better money, and now Pj. It could not be better." END >my comments, I sit here in stunned disbelief. You are a manafterall. When you looked the facts dead on, you made the right call IMO. Few poster would do this. I applaud it. Please continue to post and consider to purchase IF (IF) you find a entry price suitable to your needs as a investor. RK